Kopf-Hals-Tumoren beim alten und geriatrischen Patienten

Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Jährlich erkranken in Deutschland in etwa 15.000 Patienten an einem Plattenepithelkarzinom des Kopf-Halses mit steigender Inzidenz in den letzten Jahren. Im Vergleich zu anderen Tumoren sind die Patienten meist etwas jünger; dennoch sind in etwa die Hälfte der Patienten über 65 Jahre alt. Zu den klassischen Risikofaktoren zählen Nikotin- und Alkoholabusus, die zusätzlich auch die Entwicklung von Komorbiditäten wie kardiovaskuläre und pulmonale Erkrankungen begünstigen. Dies erschwert die Therapie insbesondere von älteren Patienten mit Kopf-Hals-Tumoren erheblich, da häufig nur durch aggressive multimodale Therapiekonzepte eine Heilung erreicht werden kann. Eine Herausforderung wird es daher zukünftig sein, altersadaptierte Therapiekonzepte zu entwickeln, um auch die Prognose ältere Patienten mit Kopf-Hals-Tumoren zu verbessern. Hierfür ist eine enge multidisziplinäre Zusammenarbeit zwischen Operateuren, Strahlentherapeuten, Onkologen aber auch Palliativmedizinern, Psychoonkologen und Ernährungsspezialisten notwendig.

Literatur

  1. Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, Ghosh D, Bowles DW, Karam SD (2016) Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer 122:1533–1543.  https://doi.org/10.1002/cncr.29956CrossRefPubMedGoogle Scholar
  2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35.  https://doi.org/10.1056/NEJMoa0912217CrossRefPubMedPubMedCentralGoogle Scholar
  3. Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA (2004) Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22:262–268CrossRefPubMedGoogle Scholar
  4. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm. Phase II study. J Clin Oncol 35:1542–1549.  https://doi.org/10.1200/JCO.2016.70.1524CrossRefPubMedGoogle Scholar
  5. Becker G, Hatami I, Xander C, Dworschak-Flach B, Olschewski M, Momm F, Deibert P, Higginson IJ, Blum HE (2011) Palliative cancer care: an epidemiologic study. J Clin Oncol 29:646–650.  https://doi.org/10.1200/JCO.2010.29.2599CrossRefPubMedGoogle Scholar
  6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMedGoogle Scholar
  7. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28.  https://doi.org/10.1016/S1470-2045(09)70311-0CrossRefPubMedGoogle Scholar
  8. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP (2006) Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis [Review]. Lancet 368:843–854CrossRefPubMedGoogle Scholar
  9. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M et al (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521–526CrossRefPubMedGoogle Scholar
  10. Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza VL, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB, LUX-H&N 1 Investigators (2016) Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol 27:1585–1593.  https://doi.org/10.1093/annonc/mdw151CrossRefPubMedPubMedCentralGoogle Scholar
  11. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867CrossRefPubMedPubMedCentralGoogle Scholar
  12. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245–1251CrossRefPubMedGoogle Scholar
  13. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098CrossRefPubMedGoogle Scholar
  14. Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Kopit J, Ferris RL (2017) Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. J Clin Oncol 35 (suppl; abstr 6019)Google Scholar
  15. Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1104–1115.  https://doi.org/10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23. PubMed PMID: 28651929
  16. Huang SH, O'Sullivan B, Waldron J, Lockwood G, Bayley A, Kim J, Cummings B, Dawson LA, Hope A, Cho J, Witterick I, Chen EX, Ringash J (2011) Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. Int J Radiat Oncol Biol Phys 79:46–51.  https://doi.org/10.1016/j.ijrobp.2009.10.052CrossRefPubMedGoogle Scholar
  17. Kwon M, Kim RB, Roh JL, Lee SW, Kim SB, Choi SH, Nam SY, Kim SY (2017) Prevalence and clinical significance of cancer cachexia based on time from treatment in advanced-stage head and neck squamous cell carcinoma. Head Neck 39:716–723.  https://doi.org/10.1002/hed.24672CrossRefPubMedGoogle Scholar
  18. Lusinchi A, Bourhis J, Wibault P, Le Ridant AM, Eschwege F (1990) Radiation therapy for head and neck cancers in the elderly. Int J Radiat Oncol Biol Phys 18:819–823CrossRefPubMedGoogle Scholar
  19. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza VL, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE, LUX-H&N 1 Investigators (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16:583–594.  https://doi.org/10.1016/S1470-2045(15)70124-5CrossRefPubMedGoogle Scholar
  20. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589.  https://doi.org/10.1200/JCO.2007.14.8841CrossRefPubMedPubMedCentralGoogle Scholar
  21. Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB (2010) Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010(21):1967–1973.  https://doi.org/10.1093/annonc/mdq077CrossRefGoogle Scholar
  22. Morgan RF, Hirata RM, Jaques DA, Hoopes JE (1982) Head and neck surgery in the aged. Am J Surg 144:449–451CrossRefPubMedGoogle Scholar
  23. Moye VA, Chandramouleeswaran S, Zhao N, Muss HB, Weissler MC, Hayes DN, Zevallos JP (2015) Elderly patients with squamous cell carcinoma of the head and neck and the benefit of multimodality therapy. Oncologist 20:159–165.  https://doi.org/10.1634/theoncologist.2013-0325CrossRefPubMedPubMedCentralGoogle Scholar
  24. Orell-Kotikangas H, Österlund P, Mäkitie O, Saarilahti K, Ravasco P, Schwab U, Mäkitie AA (2017) Cachexia at diagnosis is associated with poor survival in head and neck cancer patients. Acta Otolaryngol 26:1–11.  https://doi.org/10.1080/00016489.2016.1277263Google Scholar
  25. Pignon T, Horiot JC, Van den Bogaert W, Van Glabbeke M, Scalliet P (1996) No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer 32A:2075–2081CrossRefPubMedGoogle Scholar
  26. Pignon JP, Bourhis J, Domenge C, Designé L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949–955CrossRefPubMedGoogle Scholar
  27. Pignon JP, le Maître A, Maillard E, Bourhis J (2009) MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14.  https://doi.org/10.1016/j.radonc.2009.04.014CrossRefPubMedGoogle Scholar
  28. Sanabria A, Carvalho AL, Melo RL, Magrin J, Ikeda MK, Vartanian JG, Kowalski LP (2008) Predictive factors for complications in elderly patients who underwent head and neck oncologic surgery. Head Neck 30:170–177CrossRefPubMedGoogle Scholar
  29. Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L (2017) Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 18:323–335.  https://doi.org/10.1016/S1470-2045(17)30064-5CrossRefPubMedGoogle Scholar
  30. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742.  https://doi.org/10.1056/NEJMoa1000678CrossRefPubMedGoogle Scholar
  31. Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP (2017) Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol 35:834–841.  https://doi.org/10.1200/JCO.2016.70.5046CrossRefPubMedGoogle Scholar
  32. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.  https://doi.org/10.3322/caac.21262CrossRefPubMedGoogle Scholar
  33. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127.  https://doi.org/10.1056/NEJMoa0802656CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Westdeutsches Tumorzentrum/Innere Klinik (Tumorforschung)Universitätsklinikum EssenEssenDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations